PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
The whole armory of the drugs used in rheumatology is employed to treat systemic lupus erythematosus (SLE); how- ever, most of them have not got regulatory authorities' approval and are used off-label for SLE. The successful use of a biological agent rituximab (anti-CD20 monoclonal antibodies)...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2014-06-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1946 |
| _version_ | 1797862820729061376 |
|---|---|
| author | E. L. Nasonov S. K. Solovyev |
| author_facet | E. L. Nasonov S. K. Solovyev |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | The whole armory of the drugs used in rheumatology is employed to treat systemic lupus erythematosus (SLE); how- ever, most of them have not got regulatory authorities' approval and are used off-label for SLE. The successful use of a biological agent rituximab (anti-CD20 monoclonal antibodies) and the registration of belimumab (anti-BLyS mono- clonal antibodies) for the treatment of SLE have spurred the development of novel approaches to treating this disease. |
| first_indexed | 2024-04-09T22:25:43Z |
| format | Article |
| id | doaj.art-f1e289ab4a2f47e185000e4c66765058 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:25:43Z |
| publishDate | 2014-06-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-f1e289ab4a2f47e185000e4c667650582023-03-22T13:45:49ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922014-06-0152331132110.14412/1995-4484-2014-311-3211880PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUSE. L. Nasonov0S. K. Solovyev1Nasonova Research Institute of Rheumatology, Moscow, RussiaNasonova Research Institute of Rheumatology, Moscow, RussiaThe whole armory of the drugs used in rheumatology is employed to treat systemic lupus erythematosus (SLE); how- ever, most of them have not got regulatory authorities' approval and are used off-label for SLE. The successful use of a biological agent rituximab (anti-CD20 monoclonal antibodies) and the registration of belimumab (anti-BLyS mono- clonal antibodies) for the treatment of SLE have spurred the development of novel approaches to treating this disease.https://rsp.mediar-press.net/rsp/article/view/1946systemic lupus erythematosusmonoclonal antibodiesrituximabbelimumab. |
| spellingShingle | E. L. Nasonov S. K. Solovyev PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS Научно-практическая ревматология systemic lupus erythematosus monoclonal antibodies rituximab belimumab. |
| title | PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| title_full | PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| title_fullStr | PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| title_full_unstemmed | PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| title_short | PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| title_sort | prospects for pharmacotherapy of systemic lupus erythematosus |
| topic | systemic lupus erythematosus monoclonal antibodies rituximab belimumab. |
| url | https://rsp.mediar-press.net/rsp/article/view/1946 |
| work_keys_str_mv | AT elnasonov prospectsforpharmacotherapyofsystemiclupuserythematosus AT sksolovyev prospectsforpharmacotherapyofsystemiclupuserythematosus |